gemcitabine has been researched along with Squamous Cell Carcinoma of Head and Neck in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (69.23) | 24.3611 |
| 2020's | 4 (30.77) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, WC; Chiu, CF; Hsieh, CY; Hua, CH; Lien, MY; Lin, CC; Lin, CY; Lo, WJ | 1 |
| Feng, W; Hong, H; Huang, X; Jiang, W; Li, Z; Liang, J; Liang, L; Liu, Q; Liu, Y; Liu, ZG; Peng, Y; Xian, S; Yang, S; Zhang, Y; Zhang, Z; Zhong, G; Zhou, Y | 1 |
| Hayashi, R; Hayashi, T; Katada, A; Kishibe, K; Kobayashi, H; Komatsuda, H; Kono, M; Kosaka, A; Kumai, T; Nagato, T; Ohara, K; Ohkuri, T; Sato, R; Takahara, M; Wakisaka, R; Yamaki, H | 1 |
| Jin, CR; Xuan, YZ; Yang, KJ | 1 |
| Bartscht, T; Hakim, SG; Idel, C; Rades, D | 1 |
| Birnbaum, A; Cohen, RB; Denlinger, CS; Giles, J; He, AR; Hwang, J; Lewis, N; Moser, B; Mynderse, M; Niland, M; Plimack, ER; Sama, A; Sato, T; Walgren, R; Wallin, J; Zhang, W | 1 |
| Clark, JI; Kucuk, O; Malhotra, B; Moon, J; Urba, SG; Wolf, GT; Worden, FP | 1 |
| Chen, YW; Chou, KM; Chu, P; Liu, X; Loria, S; Wang, Y; Yen, Y; Zhou, W | 1 |
| Benasso, M; Merlano, MC; Peeters, M; Specenier, P; Szturz, P; Van den Weyngaert, D; Van Gestel, D; Van Laer, C; Vanderveken, OM; Vermorken, J; Wouters, K | 1 |
| Chang, CL; Chen, JH; Chen, TM; Lai, MT; Lee, FP; Lin, KC; Wu, CC; Wu, SY; Yen, YC; Yuan, KS | 1 |
| Carlson, D; Fury, MG; Haque, S; Pfister, D; Shen, R; Stambuk, H | 1 |
| Beniwal, P; Blair, EA; Cohen, EEW; Dekker, AJ; Gomez-Abuin, G; Haraf, D; Kocherginsky, M; Langerman, A; Portugal, L; Salama, JK; Seiwert, T; Stenson, KM; Villaflor, VM; Vokes, EE; Williams, RD; Witt, ME | 1 |
| Afrin, LB; Bielawski, J; Bostick, R; Chaudhary, U; Day, TA; Garrett-Mayer, E; Gillespie, MB; Hannun, YA; O'Brien, PE; Ogretmen, B; Saddoughi, SA; Senkal, CE; Sharma, AK; Shirai, K; Simon, GR; Wilhoit, CS | 1 |
1 review(s) available for gemcitabine and Squamous Cell Carcinoma of Head and Neck
| Article | Year |
|---|---|
Gemcitabine-Based Chemoradiation in the Treatment of Locally Advanced Head and Neck Cancer: Systematic Review of Literature and Meta-Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Deoxycytidine; Gemcitabine; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Radiation-Sensitizing Agents; Radiotherapy, Intensity-Modulated; Squamous Cell Carcinoma of Head and Neck | 2016 |
7 trial(s) available for gemcitabine and Squamous Cell Carcinoma of Head and Neck
| Article | Year |
|---|---|
Rituximab in combination with gemcitabine plus cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma: a phase I trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Feasibility Studies; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Rituximab; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2022 |
Neoadjuvant toripalimab combined with gemcitabine and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoTGP01): An open label, single-arm, phase Ib clinical trial.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Head and Neck Neoplasms; Humans; Immune Checkpoint Inhibitors; Neoadjuvant Therapy; Programmed Cell Death 1 Receptor; Receptors, Death Domain; Squamous Cell Carcinoma of Head and Neck | 2022 |
First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Proliferation; Cetuximab; Cholangiocarcinoma; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Indazoles; Male; Middle Aged; Neoplasm Staging; Niacinamide; Protein Kinase Inhibitors; Ramucirumab; Squamous Cell Carcinoma of Head and Neck | 2019 |
Phase II trial of biweekly gemcitabine and paclitaxel with recurrent or metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group study S0329.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Feasibility Studies; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2014 |
A phase 2 study of pemetrexed plus gemcitabine every 2 weeks for patients with recurrent or metastatic head and neck squamous cell cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Glutamates; Guanine; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Squamous Cell; Pemetrexed; Recurrence; Squamous Cell Carcinoma of Head and Neck | 2011 |
Phase II trial of pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated patients with squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Pemetrexed; Prospective Studies; Radiotherapy; Squamous Cell Carcinoma of Head and Neck | 2011 |
Results of a phase II trial of gemcitabine plus doxorubicin in patients with recurrent head and neck cancers: serum C₁₈-ceramide as a novel biomarker for monitoring response.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Squamous Cell; Ceramides; Deoxycytidine; Doxorubicin; Gemcitabine; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Middle Aged; Recurrence; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2011 |
5 other study(ies) available for gemcitabine and Squamous Cell Carcinoma of Head and Neck
| Article | Year |
|---|---|
Brachyury-targeted immunotherapy combined with gemcitabine against head and neck cancer.
Topics: Animals; B7-H1 Antigen; Cell Line, Tumor; Epitopes; Gemcitabine; Head and Neck Neoplasms; Immunotherapy; Mice; Programmed Cell Death 1 Receptor; Squamous Cell Carcinoma of Head and Neck | 2023 |
TGF-β downregulation overcomes gemcitabine resistance in oral squamous cell carcinoma.
Topics: Animals; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Mice; Mouth Neoplasms; Squamous Cell Carcinoma of Head and Neck; Transforming Growth Factor beta; Xenograft Model Antitumor Assays | 2020 |
Re-irradiation with 36 Gy (1.5 Gy Twice Daily) Plus Paclitaxel for Advanced Recurrent and Previously Irradiated SCCHN is Feasible.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Chemoradiotherapy; Deoxycytidine; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Neoplasm Recurrence, Local; Paclitaxel; Re-Irradiation; Squamous Cell Carcinoma of Head and Neck | 2018 |
Expression of DNA translesion synthesis polymerase η in head and neck squamous cell cancer predicts resistance to gemcitabine and cisplatin-based chemotherapy.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; DNA-Directed DNA Polymerase; Drug Resistance, Neoplasm; Epithelial Cells; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Male; Middle Aged; Prognosis; Squamous Cell Carcinoma of Head and Neck | 2013 |
Survival prognostic factors for metachronous second primary head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Hydroxyurea; Male; Methotrexate; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Paclitaxel; Prognosis; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Taxoids; Treatment Outcome; Young Adult | 2017 |